Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $12.00

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned an average rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.00.

Several analysts recently commented on the stock. Weiss Ratings lowered shares of SAB Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen raised SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Chardan Capital increased their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Citigroup started coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, June 15th.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABS opened at $3.72 on Friday. The company has a 50 day moving average of $3.73 and a 200-day moving average of $3.77. The firm has a market cap of $338.48 million, a P/E ratio of -2.86 and a beta of 0.53. SAB Biotherapeutics has a twelve month low of $1.85 and a twelve month high of $5.15. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). As a group, analysts anticipate that SAB Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. purchased a new position in shares of SAB Biotherapeutics in the first quarter worth approximately $29,000. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP purchased a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $32,000. State of Wyoming acquired a new stake in SAB Biotherapeutics during the 4th quarter valued at $34,000. Finally, Virtu Financial LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.